MSN and breast carcinoma: We found that breast cancer patients with high FBXW2/low Moesin levels have significantly better RFS compared to those with low FBXW2/high Moesin (Supplementary Fig. S1G), suggesting that the expression levels of both FBXW2 and Moesin could be used as prognostic biomarkers in breast cancer.